NCT02310789View on ClinicalTrials.gov

(Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil?

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

August 2, 2016

Study Completion Date

August 23, 2017

Conditions

Cystic Fibrosis

Interventions

DRUG

Ivacaftor

150mg administered orally twice daily.

DRUG

β-Adrenergic cocktail

Administered subcutaneously to induce sweating. Cocktail composed of atropine (280µM), isoproterenol (160µM), and aminophylline (20 mM).

DRUG

Pilocarpine Nitrate 5%

Administered subcutaneously using Macroduct sweat stimulator device.

DEVICE

Macroduct sweat stimulator

Trial Locations (1)

94305

Stanford Hospital and Clinics, Stanford

All Listed Sponsors

lead

Richard Barry Moss

OTHER

NCT02310789 - (Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil? | Biotech Hunter | Biotech Hunter